药物诱导的帕金森症:诊断和治疗
Hannah Conn1, Joseph Jankovic1
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
Expert opinion on drug safety
|October 17, 2024
概括
药物诱导的帕金森症 (DIP) 模仿异常性帕金森病,由多巴胺受体阻断剂引起. 早期怀疑和诊断测试对于管理DIP至关重要,通常涉及药物调整.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物诱导的帕金森症 (DIP) 是一种常见的阳性运动障碍.
- DIP表现为震,缓慢和步行不稳定,临床上类似于异常帕金森病.
- 诊断需要有接触多巴胺受体阻断剂 (DRBA) 的病史.
研究的目的:
- 审查DIP的流行病学,病理生理学,临床特征,诊断测试和治疗.
- 为临床医生提供有关识别和管理DIP的指导.
主要方法:
- 在PubMed.com进行了全面的文献搜索.
- 该搜索涵盖了2013年1月至2024年1月期间发表的文章.
主要成果:
- 在服用DRBAs的患者中,DIP发作通常是急性到亚急性.
- 可能需要像DaTscans和皮肤活检这样的辅助测试来区分DIP和异常性帕金森病.
- 治疗包括停止或调整违规的DRBA,在抗精神病药物诱导的病例中,可以选择切换到奎平或克洛扎平.
结论:
- 临床医生的怀疑是诊断DRBA患者DIP的关键.
- 确定的诊断可能需要先进的测试,因为临床相似性与异常帕金森病.
- 治疗重点是去除致病原体,不建议使用预防性抗胆固醇药物.
相关概念视频
Parkinson's Disease: Treatment
231
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
231
Parkinson's Disease: Overview
487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Psychosis: Goals of Pharmacotherapy
109
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
109
Psychosis and Antipsychotic Drugs: Overview
186
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
186
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39


